Use of apatinib combined with pemetrexed for advanced ovarian cancer: A case report

INTRODUCTION: Ovarian cancer is the most deadly gynecologic cancer, and the therapy is very difficult. Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2. At present, there are few studies or case reports on apatinib treatment for patients with ovar...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Huiting, Xiao, Min, Liu, Sufen, Shi, Ruxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076125/
https://www.ncbi.nlm.nih.gov/pubmed/29979376
http://dx.doi.org/10.1097/MD.0000000000011036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076125/
https://www.ncbi.nlm.nih.gov/pubmed/29979376
http://dx.doi.org/10.1097/MD.0000000000011036

Ejemplares similares